CoChat

Short Chain Fatty Acids, pancreatic dysfunction and type 2 diabetes

Mandaliya, Dipeeka K., Seshadri, Sriram · 2019 · Pancreatology
Cited by 110

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

The microbiota living in gut influence the immune response, metabolism, mood and behavior. The diet plays a pivotal role in maintaining healthy gut microbiota composition and its fermentation leads to production of Short Chain Fatty Acids (SCFAs) mainly acetate, propionate and butyrate. During pancreatic dysfunction, insulin mediated suppression of glucagon is impaired leading to uncontrolled glucose production by liver and state of hyperglycemia. Insulin and glucagon balance is as important as insulin sensitivity which is reduced during Type 2 Diabetes (T2D). Glucagon like peptide-1 (GLP1) produced by Intestinal epithelial cells regulates insulin and glucagon secretion directly via GLP1 receptor on pancreatic cells or via nervous system. But half-life period of GLP1 is very short i.e. about 2 min, after which it is cleaved and inactivated. SCFAs are well documented to induce GLP1 but its direct effect on pancreatic dysfunction has not been reported. This review opens a new avenue to study the role of SCFAs as treatment to pancreatic dysfunction and T2D.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pan.2019.01.021

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 41

  1. Larsson, 2000, Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance, Diabetes Care, 23, 650, 10.2337/diacare.23.5.650 · DOI · Paper page
  2. Rui, 2014, Energy metabolism in the liver, Comprehensive Physiology, 4, 177, 10.1002/j.2040-4603.2014.tb00548.x · doi:10.1002/j.2040-4603.2014.tb00548.x · Paper page
  3. Doyle, 2007, Mechanisms of action of glucagon-like peptide 1 in the pancreas, Pharmacol Ther, 113, 546, 10.1016/j.pharmthera.2006.11.007 · DOI · Paper page
  4. Brown, 2012, Choosing between glp-1 receptor agonists and dpp-4 inhibitors: a pharmacological perspective, Journal of Nutrition and Metabolism, 2012, 10, 10.1155/2012/381713 · DOI
  5. Lin, 2012, Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms, PLoS One, 7
  6. Tang, 2015, Loss of ffa2 and ffa3 increases insulin secretion and improves glucose tolerance in type 2 diabetes, Nat Med, 21, 173, 10.1038/nm.3779 · DOI · Paper page
  7. Roy, 2006, vol. 21, 351
  8. Fleming, 1991, Nutrient utilization by cells isolated from rat jejunum, cecum and colon, J Nutr, 121, 869
  9. Yoon, 2003, Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in korea, J Clin Endocrinol Metab, 88, 2300, 10.1210/jc.2002-020735 · DOI · Paper page
  10. Unger, 2010, Paracrinology of islets and the paracrinopathy of diabetes, Proc Natl Acad Sci U S A, 107, 16009, 10.1073/pnas.1006639107 · DOI · Paper page
  11. Kawamori, 2009, Insulin signaling in alpha cells modulates glucagon secretion in vivo, Cell Metabol, 9, 350, 10.1016/j.cmet.2009.02.007 · DOI · Paper page
  12. Rorsman, 2008, K(atp)-channels and glucose-regulated glucagon secretion, Trends Endocrinol Metabol: TEM (Trends Endocrinol Metab), 19, 277, 10.1016/j.tem.2008.07.003 · DOI
  13. Kawamori, 2011, Growth factor signalling in the regulation of alpha-cell fate, Diabetes Obes Metab, 13, 21, 10.1111/j.1463-1326.2011.01442.x · DOI
  14. Lopez Soto, 2014, Free fatty acid receptor 3 is a key target of short chain fatty acid. What is the impact on the sympathetic nervous system?, Channels, 8, 169, 10.4161/chan.28956 · DOI
  15. Fu, 2013, Regulation of insulin synthesis and secretion and pancreatic beta-cell dysfunction in diabetes, Curr Diabetes Rev, 9, 25, 10.2174/157339913804143225 · DOI · Paper page
  16. Kitamura, 2013, The role of foxo1 in beta-cell failure and type 2 diabetes mellitus, Nat Rev Endocrinol, 9, 615, 10.1038/nrendo.2013.157 · DOI · Paper page
  17. Papa, 2012, Endoplasmic reticulum stress, pancreatic beta-cell degeneration, and diabetes, Cold Spring Harbor perspectives in medicine, 2, 10.1101/cshperspect.a007666 · DOI · Paper page
  18. Lee, 2010, Er stress is implicated in mitochondrial dysfunction-induced apoptosis of pancreatic beta cells, Mol Cell, 30, 545, 10.1007/s10059-010-0161-5 · DOI
  19. Wang, 2016, Bridges between mitochondrial oxidative stress, er stress and mtor signaling in pancreatic beta cells, Cell Signal, 28, 1099, 10.1016/j.cellsig.2016.05.007 · DOI · Paper page
  20. Harding, 2001, Diabetes mellitus and exocrine pancreatic dysfunction in perk-/- mice reveals a role for translational control in secretory cell survival, Mol Cell, 7, 1153, 10.1016/S1097-2765(01)00264-7 · DOI · Paper page
  21. Back, 2012, Endoplasmic reticulum stress and type 2 diabetes, Annu Rev Biochem, 81, 767, 10.1146/annurev-biochem-072909-095555 · DOI · Paper page
  22. Kitiphongspattana, 2007, Protective role for nitric oxide during the endoplasmic reticulum stress response in pancreatic beta-cells, Am J Physiol Endocrinol Metab, 292, E1543, 10.1152/ajpendo.00620.2006 · DOI · Paper page
  23. Lim, 2011, Mitochondria-targeted antioxidants protect pancreatic beta-cells against oxidative stress and improve insulin secretion in glucotoxicity and glucolipotoxicity, Cell Physiol Biochem: international journal of experimental cellular physiology, biochemistry, and pharmacology, 28, 873, 10.1159/000335802 · DOI · Paper page
  24. Rutter, 2015, Pancreatic beta-cell identity, glucose sensing and the control of insulin secretion, Biochem J, 466, 203, 10.1042/BJ20141384 · DOI · Paper page
  25. Li, 2008, Combination of glp-1 and sodium butyrate promote differentiation of pancreatic progenitor cells into insulin-producing cells, Tissue Cell, 40, 437, 10.1016/j.tice.2008.04.006 · DOI
  26. Li, 2005, Beta-cell pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1, Diabetes, 54, 482, 10.2337/diabetes.54.2.482 · DOI · Paper page
  27. Christensen, 2011, Histone deacetylase (hdac) inhibition as a novel treatment for diabetes mellitus, Mol Med, 17, 378, 10.2119/molmed.2011.00021 · DOI · Paper page
  28. Goicoa, 2006, Sodium butyrate activates genes of early pancreatic development in embryonic stem cells, Clon Stem Cell, 8, 140, 10.1089/clo.2006.8.140 · DOI
  29. Calanna, 2014, Alpha- and beta-cell abnormalities in haemoglobin a1c-defined prediabetes and type 2 diabetes, Acta Diabetol, 51, 567, 10.1007/s00592-014-0555-5 · DOI
  30. Matsuyama, 1988, Glucagon-like peptide-1 (7-36 amide): a potent glucagonostatic and insulinotropic hormone, Diabetes Res Clin Pract, 5, 281, 10.1016/S0168-8227(88)80063-9 · DOI
  31. Godoy-Matos, 2014, The role of glucagon on type 2 diabetes at a glance, Diabetol Metab Syndrome, 6, 91, 10.1186/1758-5996-6-91 · DOI · Paper page
  32. Nauck, 1997, Glucagon-like peptide 1 (glp-1) as a new therapeutic approach for type 2-diabetes, Exp Clin Endocrinol Diabetes: official journal, German Society of Endocrinology [and] German Diabetes Association, 105, 187, 10.1055/s-0029-1211750 · DOI · Paper page
  33. Psichas, 2005, The short chain fatty acid propionate stimulates glp-1 and pyy secretion via free fatty acid receptor 2 in rodents, Int J Obes, 39, 424
  34. Puddu, 2014, Evidence for the gut microbiota short-chain fatty acids as key pathophysiological molecules improving diabetes, Mediat Inflamm, 2014, 162021, 10.1155/2014/162021 · DOI · Paper page
  35. Perfetti, 2004, The role of glp-1 in the life and death of pancreatic beta cells, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 36, 804, 10.1055/s-2004-826167 · DOI · Paper page
  36. Priyadarshini, 2016, Scfa receptors in pancreatic beta cells: novel diabetes targets?, Trends Endocrinol Metabol: TEM (Trends Endocrinol Metab), 27, 653, 10.1016/j.tem.2016.03.011 · DOI · Paper page
  37. Wang, 2010, Cytokines in the progression of pancreatic beta-cell dysfunction, International journal of endocrinology, 2010, 515136, 10.1155/2010/515136 · DOI · Paper page
  38. Westwell-Roper, 2014, Is there a role for the adaptive immune system in pancreatic beta cell failure in type 2 diabetes?, Diabetologia, 57, 447, 10.1007/s00125-013-3151-2 · DOI
  39. Mattace Raso, 2013, Effects of sodium butyrate and its synthetic amide derivative on liver inflammation and glucose tolerance in an animal model of steatosis induced by high fat diet, PLoS One, 8, 10.1371/journal.pone.0068626 · DOI · Paper page
  40. Vinolo, 2011, Regulation of inflammation by short chain fatty acids, Nutrients, 3, 858, 10.3390/nu3100858 · DOI · Paper page
  41. Tedelind, 2007, Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease, World J Gastroenterol, 13, 2826, 10.3748/wjg.v13.i20.2826 · DOI · Paper page

Cited by

See all 110

Metadata

Authors
Mandaliya, D. K., & Seshadri, S.
Venue
Pancreatology
Publisher
Elsevier BV
Published
2019-03
Volume
19
Issue
2
Pages
280-284
ISSN
1424-3903 (ISSN-L)
OpenAlex
W2913532408
Cited by
110
References
29
FWCI
4.08
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • University Grant CommissionUniversity Grant Commission (UGC) (372817)
  • Nirma Education and Research Foundation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.